Another phase I trial demonstrated that twelve B-ALL patients (57%) achieved a CR with 9 measurable residual disease (MRD) negative after CD22 CAR-T cell infusion, including 5 patients with CD19-negative recurrence after treatment with CD19 CAR-T cells (36). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.